The aryl hydrocarbon receptor shapes monocyte transcriptional responses to interleukin-4 by prolonging STAT6 binding to promoters.


Journal

Science signaling
ISSN: 1937-9145
Titre abrégé: Sci Signal
Pays: United States
ID NLM: 101465400

Informations de publication

Date de publication:
15 Oct 2024
Historique:
medline: 15 10 2024
pubmed: 15 10 2024
entrez: 15 10 2024
Statut: ppublish

Résumé

Cytokines induce functional and metabolic adaptations in immune cells, typically through transcriptional responses that can be influenced by other extracellular signals and by intracellular factors. The binding of the cytokine interleukin-4 (IL-4) to its receptor induces the phosphorylation and activation of the transcription factor STAT6. The aryl hydrocarbon receptor (AhR), a transcription factor activated by various endogenous and microbe-derived metabolites, modulates the responses of immune cells to danger signals or inflammatory mediators such as cytokines. Here, we investigated cross-talk between the AhR and signaling stimulated by IL-4 in human and mouse monocytes. AhR activation was required for a subset of IL-4-induced transcriptional responses and inhibited the IL-4-induced metabolic switch to fatty acid β-oxidation. The promoters of the genes that were induced by IL-4 in an AhR-dependent manner lacked canonical AhR binding sites, implying a nongenomic mechanism of AhR action. Mechanistically, AhR activation reduced the activity of SHP-1, a phosphatase that targets and inhibits STAT6, and prolonged STAT6 phosphorylation and binding to specific target loci, thus extending the duration of STAT6 activity. Our results identify AhR as a key player in the molecular control of responses to IL-4 in monocytes and suggest a nongenomic mechanism through which AhR ligands may influence the functional responses of cells to IL-4.

Identifiants

pubmed: 39405377
doi: 10.1126/scisignal.adn6324
doi:

Substances chimiques

Receptors, Aryl Hydrocarbon 0
STAT6 Transcription Factor 0
Interleukin-4 207137-56-2
STAT6 protein, human 0
Stat6 protein, mouse 0
AHR protein, human 0
Protein Tyrosine Phosphatase, Non-Receptor Type 6 EC 3.1.3.48
IL4 protein, human 0
Basic Helix-Loop-Helix Transcription Factors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eadn6324

Auteurs

Alba de Juan (A)

Institut Curie, PSL Research University, INSERM, U932, 26 rue d'Ulm, Paris, France.

Darawan Tabtim-On (D)

Institut Curie, PSL Research University, INSERM, U932, 26 rue d'Ulm, Paris, France.

Alice Coillard (A)

Institut Curie, PSL Research University, INSERM, U932, 26 rue d'Ulm, Paris, France.

Burkhard Becher (B)

Institute of Experimental Immunology, University of Zurich, 8057 Zurich, Switzerland.

Christel Goudot (C)

Institut Curie, PSL Research University, INSERM, U932, 26 rue d'Ulm, Paris, France.

Elodie Segura (E)

Institut Curie, PSL Research University, INSERM, U932, 26 rue d'Ulm, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH